RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics

Nature Immunology

Volumn 17, Issue 12, 2016, Pages 1352-1360

  Salzer, Elisabeth ^a,b   Cagdas, Deniz ^c   Hons, Miroslav ^d   MacE, Emily M ^e   Garncarz, Wojciech ^a,b   Petronczki, Özlem Yüce ^a,b   Platzer, René ^f   Pfajfer, Laurène ^a,b   Bilic, Ivan ^a   Ban, Sol A ^a   Willmann, Katharina L ^a   Mukherjee, Malini ^e   Supper, Verena ^f   Hsu, Hsiang Ting ^e   Banerjee, Pinaki P ^e   Sinha, Papiya ^e   McClanahan, Fabienne ^g   Zlabinger, Gerhard J ^h   Pickl, Winfried F ^h   Gribben, John G ^g   Stockinger, Hannes ^f   Bennett, Keiryn L ^a   Huppa, Johannes B ^f   Dupré, Loïc ^a,b,i   Sanal, Özden ^c   Jäger, Ulrich ^j   Sixt, Michael ^d   Tezcan, Ilhan ^c   Orange, Jordan S ^e   Boztug, Kaan ^a,b,j,k   more..

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c HACETTEPE UNIVERSITY   (Turkey)

^d INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA   (Austria)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ CHU PURPAN   (France)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; DYNEIN ADENOSINE TRIPHOSPHATASE; DYNLL1 PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; RASGRP1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; DNA BINDING PROTEIN; RASGRP1 PROTEIN, HUMAN; SMALL INTERFERING RNA; THALIDOMIDE;

ALLELE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CASE REPORT; CELL MOTILITY; CHILD; CONSANGUINEOUS MARRIAGE; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; ENZYME PHOSPHORYLATION; EXOME; GENE; GENE MAPPING; GENETIC DATABASE; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOLECULAR DYNAMICS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RASGRP1 GENE; SCHOOL CHILD; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ADOLESCENT; ANALOGS AND DERIVATIVES; CELL MOTION; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; FEMALE; GENE REARRANGEMENT; GENETICS; HEK293 CELL LINE; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; JURKAT CELL LINE; MALE; METABOLISM; MUTATION; PEDIGREE; T LYMPHOCYTE;

ACTINS; ADOLESCENT; ANGIOGENESIS INHIBITORS; B-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CHILD; CYTOSKELETON; CYTOTOXICITY, IMMUNOLOGIC; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DYNEINS; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOLOGIC DEFICIENCY SYNDROMES; JURKAT CELLS; KILLER CELLS, NATURAL; MALE; MUTATION; PEDIGREE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84992410702     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3575     Document Type: Article

References (69)

1. Roose, J. & Weiss, A. T cells: getting a GRP on Ras. Nat. Immunol. 1, 275-276 (2000).
2. Stone, J.C. Regulation and function of the RasGRP family of Ras activators in blood cells. Genes Cancer 2, 320-334 (2011).
3. Downward, J., Graves, J.D., Warne, P.H., Rayter, S. & Cantrell, D.A. Stimulation of p21ras upon T-cell activation. Nature 346, 719-723 (1990).
4. Kremer, K.N., Kumar, A. & Hedin, K.E. G alpha i2 and ZAP-70 mediate RasGRP1 membrane localization and activation of SDF-1-induced T cell functions. J. Immunol. 187, 3177-3185 (2011).
5. Dower, N.A. et al. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat. Immunol. 1, 317-321 (2000).
6. Khanna, R. & Burrows, S.R. Human immunology: a case for the ascent of non-furry immunology. Immunol. Cell Biol. 89, 330-331 (2011).
7. Mestas, J. & Hughes, C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
8. Waterston, R.H. et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520-562 (2002).
9. Notarangelo, L.D. Functional T cell immunodeficiencies (with T cells present). Annu. Rev. Immunol. 31, 195-225 (2013).
10. Notarangelo, L.D. Partial defects of T-cell development associated with poor T-cell function. J. Allergy Clin. Immunol. 131, 1297-1305 (2013).
11. Picard, C. et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J. Clin. Immunol. 35, 696-726 (2015).
12. Bousfiha, A. et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J. Clin. Immunol. 35, 727-738 (2015).
13. Espinós, C. et al. Mutations in the urocanase gene UROC1 are associated with urocanic aciduria. J. Med. Genet. 46, 407-411 (2009).
14. Chen, Y. et al. Differential requirement of RasGRP1 for T cell development and activation. J. Immunol. 189, 61-71 (2012).
15. Warnecke, N. et al. TCR-mediated Erk activation does not depend on Sos and Grb2 in peripheral human T cells. EMBO Rep. 13, 386-391 (2012).
16. Jun, J.E., Rubio, I. & Roose, J.P. Regulation of ras exchange factors and cellular localization of ras activation by lipid messengers in T cells. Front. Immunol. 4, 239 (2013).
17. Depeille, P. et al. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat. Cell Biol. 17, 804-815 (2015).
18. Shen, S. et al. Critical roles of RasGRP1 for invariant NKT cell development. J. Immunol. 187, 4467-4473 (2011).
19. Montoya, C.J. et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122, 1-14 (2007).
20. Priatel, J.J. et al. Chronic immunodeficiency in mice lacking RasGRP1 results in CD4 T cell immune activation and exhaustion. J. Immunol. 179, 2143-2152 (2007).
21. Ma, C.S. & Deenick, E.K. Human T follicular helper (Tfh) cells and disease. Immunol. Cell Biol. 92, 64-71 (2014).
22. Bartlett, A., Buhlmann, J.E., Stone, J., Lim, B. & Barrington, R.A. Multiple checkpoint breach of B cell tolerance in Rasgrp1-deficient mice. J. Immunol. 191, 3605-3613 (2013).
23. Coughlin, J.J., Stang, S.L., Dower, N.A. & Stone, J.C. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J. Immunol. 175, 7179-7184 (2005).
24. Sun, C. et al. High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nat. Genet. 48, 323-330 (2016).
25. Tangye, S.G., Ferguson, A., Avery, D.T., Ma, C.S. & Hodgkin, P.D. Isotype switching by human B cells is division-associated and regulated by cytokines. J. Immunol. 169, 4298-4306 (2002).
26. Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785-798 (2004).
27. Perussia, B., Chen, Y. & Loza, M.J. Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell. Mol. Immunol. 42, 385-395 (2005).
28. Navarro, M.N. & Cantrell, D.A. Serine-threonine kinases in TCR signaling. Nat. Immunol. 15, 808-814 (2014).
29. Okamura, S.M., Oki-Idouchi, C.E. & Lorenzo, P.S. The exchange factor and diacylglycerol receptor RasGRP3 interacts with dynein light chain 1 through its C-terminal domain. J. Biol. Chem. 281, 36132-36139 (2006).
30. Rodríguez-Crespo, I. et al. Identification of novel cellular proteins that bind to the LC8 dynein light chain using a pepscan technique. FEBS Lett. 503, 135-141 (2001).
31. Huse, M. Microtubule-organizing center polarity and the immunological synapse: protein kinase C and beyond. Front. Immunol. 3, 235 (2012).
32. Mentlik, A.N., Sanborn, K.B., Holzbaur, E.L. & Orange, J.S. Rapid lytic granule convergence to the MTOC in natural killer cells is dependent on dynein but not cytolytic commitment. Mol. Biol. Cell 21, 2241-2256 (2010).
33. Roose, J.P., Mollenauer, M., Gupta, V.A., Stone, J. & Weiss, A. A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells. Mol. Cell. Biol. 25, 4426-4441 (2005).
34. Li, R. & Gundersen, G.G. Beyond polymer polarity: how the cytoskeleton builds a polarized cell. Nat. Rev. Mol. Cell Biol. 9, 860-873 (2008).
35. Liu, Y., Zhu, M., Nishida, K., Hirano, T. & Zhang, W. An essential role for RasGRP1 in mast cell function and IgE-mediated allergic response. J. Exp. Med. 204, 93-103 (2007).
36. Ramsay, A.G. et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 121, 2704-2714 (2013).
37. Richardson, P.G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679-686 (2010).
38. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
39. Gandhi, A.K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164, 811-821 (2014).
40. Casanova, J.L., Conley, M.E., Seligman, S.J., Abel, L. & Notarangelo, L.D. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J. Exp. Med. 211, 2137-2149 (2014).
41. Fuller, D.M. et al. Regulation of RasGRP1 function in T cell development and activation by its unique tail domain. PLoS One 7, e38796 (2012).
42. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503-510 (2008).
43. Thrasher, A.J. & Burns, S.O. WASP: a key immunological multitasker. Nat. Rev. Immunol. 10, 182-192 (2010).
44. Lanzi, G. et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J. Exp. Med. 209, 29-34 (2012).
45. McGhee, S.A. & Chatila, T.A. DOCK8 immune deficiency as a model for primary cytoskeletal dysfunction. Dis. Markers 29, 151-156 (2010).
46. Liu, X., Kapoor, T.M., Chen, J.K. & Huse, M. Diacylglycerol promotes centrosome polarization in T cells via reciprocal localization of dynein and myosin II. Proc. Natl. Acad. Sci. USA 110, 11976-11981 (2013).
47. Schroeder, C.M., Ostrem, J.M., Hertz, N.T. & Vale, R.D. A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region. eLife 3, e03351 (2014).
48. Jayappa, K.D. et al. Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein. J. Virol. 89, 3497-3511 (2015).
49. Zenz, T. Exhausting T cells in CLL. Blood 121, 1485-1486 (2013).
50. Salzer, E. et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 98, 473-478 (2013).
51. Willmann, K.L. et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat. Commun. 5, 5360 (2014).
52. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
53. Dupré, L. et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum. Gene Ther. 17, 303-313 (2006).
54. Dupré, L. et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol. Ther. 10, 903-915 (2004).
55. Pichlmair, A. et al. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature 487, 486-490 (2012).
56. Glatter, T., Wepf, A., Aebersold, R. & Gstaiger, M. An integrated workflow for charting the human interaction proteome: insights into the PP2A system. Mol. Syst. Biol. 5, 237 (2009).
57. Dow, L.E. et al. A pipeline for the generation of shRNA transgenic mice. Nat. Protoc. 7, 374-393 (2012).
58. Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628-1640 (2011).
59. Ran, F.A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
60. Sanjana, N.E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
61. Brinkman, E.K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).
62. Boztug, K. et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat. Genet. 46, 1021-1027 (2014).
63. Mellacheruvu, D. et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods 10, 730-736 (2013).
64. Vasconcelos, Z. et al. Individual human cytotoxic T lymphocytes exhibit intraclonal heterogeneity during sustained killing. Cell Rep. 11, 1474-1485 (2015).
65. Huppa, J.B. et al. TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. Nature 463, 963-967 (2010).
66. Fairhead, M., Krndija, D., Lowe, E.D. & Howarth, M. Plug-and-play pairing via defined divalent streptavidins. J. Mol. Biol. 426, 199-214 (2014).
67. Howarth, M. et al. A monovalent streptavidin with a single femtomolar biotin binding site. Nat. Methods 3, 267-273 (2006).
68. Banerjee, P.P. & Orange, J.S. Quantitative measurement of F-actin accumulation at the NK cell immunological synapse. J. Immunol. Methods 355, 1-13 (2010).
69. Trifari, S. et al. Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J. Immunol. 177, 7451-7461 (2006).